Studies long-term blood-thinning medicine safety in people with heart disease
Follows adults with chronic coronary heart disease taking long-term antiplatelet medicine to track complications.
Plain-language title generated from the registry record
Registry title: REGistry of Long-term AnTithrombotic TherApy-1
Key facts
- Where
- Moscow, RussiaSee the site
Where in Russia
- National Medical Research Center for Cardiology, Ministry of Health of Russian FederationMoscow, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Trial code
- NCT04347200
- Record updated
- 1 May 2026
- Original description
To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with chronic coronary syndromesRead full original descriptionShow less
Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes
To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with chronic coronary syndromes
Inclusion: coronary artery disease , confirmed by history of myocardial infarction, or revascularization, or definitive evidence of CAD on imaging.
Exclusion: Acute coronary syndrome within 12 months before inclusion; Stroke within 6 months before inclusion; Severe chronic heart failure (NYHA IV); Severe liver or muscle disease; Severe kidney disease / renal failure with creatinine > 3 mg/dl; Subjects who are unwilling or unable to provide informed consent; Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention -.